Sepsis is a life-threatening condition. Programmed cell death 1 protein (PD-1), a negative costimulatory molecule, is suggested to be involved in pathogenesis as mortality is associated with high expression and as neutralizing antibodies improve survival in a mouse model. The PD-1 gene harbors an intronic single-nucleotide polymorphism, rs11568821, which is located in a transcription factor–binding site and supposed to affect PD-1 transcription.
Objective
This study aimed at investigating whether mortality (90-day) among patients with sepsis associates with PD-1 rs11568821 genotypes.
Methods
Adult white patients with sepsis from the surgical intensive care units of a university medical center were followed up for 90 days, and mortality was recorded as primary outcome variable. Blood samples were taken for PD-1 rs11568821 genotyping. Sequential Organ Failure Assessment scores increased at enrollment and during the observation period to monitor morbidity.
Results
Two hundred nineteen critically ill patients with sepsis were enrolled in this investigation. Ninety-day mortality was significantly higher among G homozygotes than among A allele carriers (P = 0.0032). During intensive care unit stay, G homozygotes experienced higher Sequential Organ Failure Assessment scores (P < 0.001) and a higher demand of vasopressor therapy (P = 0.0107).
Conclusions
Data provide first associative evidence for PD-1 rs11568821 as a prognostic indicator in patients with sepsis.
WangTS, DengJC.Molecular and cellular aspects of sepsis-induced immunosuppression. J Mol Med (Berl). 2008; 86: 495–506.
7.
BoomerJS, Shuherk-ShafferJ, HotchkissRS, . A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care. 2012; 16: R112.
8.
KhamsiR.Execution of sepsis trials needs an overhaul, experts say. Nat Med. 2012; 18: 998–999.
9.
BrahmamdamP, InoueS, UnsingerJ, . Delayed administration of anti–PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010; 88: 233–240.
10.
FranciscoLM, SagePT, SharpeAH.The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236: 219–242.
11.
SaidEA, DupuyFP, TrautmannL, . Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med. 2010; 16: 452–459.
12.
ZhangY, LiJ, LouJ, . Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011; 15: R70.
13.
HuangX, VenetF, WangYL, . PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A. 2009; 106: 6303–6308.
14.
TopalianSL, HodiFS, BrahmerJR, . Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443–2454.
15.
ProkuninaL, Castillejo-LopezC, ObergF, . A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002; 32: 666–669.
16.
KristjansdottirH, SteinssonK, GunnarssonI, . Lower expression levels of the programmed death 1 receptor on CD4+CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. Arthritis Rheum. 2010; 62: 1702–1711.
17.
KeirME, ButteMJ, FreemanGJ, . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26: 677–704.
KronerA, MehlingM, HemmerB, . A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol. 2005; 58: 50–57.
20.
HoffmannTW, HalimiJM, BuchlerM, . Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation. J Med Genet. 2010; 47: 54–58.
21.
Vidal-CastineiraJR, Lopez-VazquezA, Alonso-AriasR, . A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. J Hepatol. 2012; 56: 1230–1238.
22.
BoneRC, BalkRA, CerraFB, . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest. 2009; 136: e28.
23.
LevyMM, FinkMP, MarshallJC, . 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31: 1250–1256.
24.
VincentJL, de MendoncaA, CantraineF, . Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998; 26: 1793–1800.
25.
KnausWA, DraperEA, WagnerDP, . APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13: 818–829.
26.
MertensJ, RamadoriG, MihmS.Functional relevance of the IRF-1 promoter polymorphism rs2549009 on transcriptional activity in a native genomic environment. Hum Mol Genet. 2010; 19: 4587–4594.
27.
BrownKE, FreemanGJ, WherryEJ, . Role of PD-1 in regulating acute infections. Curr Opin Immunol. 2010; 22: 397–401.
28.
JinHT, AhmedR, OkazakiT.Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011; 350: 17–37.
29.
WeberSU, ScheweJC, LehmannLE, . Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis. Crit Care. 2008; 12: R128.
30.
FrankAJ, SheuCC, ZhaoY, . BCL2 genetic variants are associated with acute kidney injury in septic shock. Crit Care Med. 2012; 40: 2116–2123.
31.
AlvarezIB, PasquinelliV, JuradoJO, . Role played by the programmed death-1–programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis. 2010; 202: 524–532.
32.
FrebelH, NindlV, SchuepbachRA, . Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med. 2012; 209: 2485–2499.
33.
Lazar-MolnarE, ChenB, SweeneyKA, . Programmed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A. 2010; 107: 13402–13407.
34.
MolloyS.PD1 turns down the heat. Nat Rev Microbiol. 2010; 8: 612.
35.
VeluV, TitanjiK, ZhuB, . Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009; 458: 206–210.
36.
PalmerBE, NeffCP, LecureuxJ, . In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol. 2013; 190: 211–219.
37.
LipsonEJ, SharfmanWH, DrakeCG, . Durable cancer regression off-treatment and effective reinduction therapy with an anti–PD-1 antibody. Clin Cancer Res. 2013; 19: 462–468.
38.
BrahmerJR, DrakeCG, WollnerI, . Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28: 3167–3175.
39.
HuaZ, LiD, XiangG, . PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. Breast Cancer Res Treat. 2011; 129: 195–201.
40.
HayashiM, KoukiT, TakasuN, . Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves’ disease in Japanese patients. Eur J Endocrinol. 2008; 158: 817–822.
